Arcus Biosciences Inc’s recent filing unveils that its 10% Owner GILEAD SCIENCES, INC. acquired Company’s shares for reported $15.0 million on Feb 18 ’25. In the deal valued at $11.00 per share,1,363,636 shares were bought. As a result of this transaction, GILEAD SCIENCES, INC. now holds 31,424,760 shares worth roughly $347.87 million.
Then, Goeltz II Robert C. sold 3,594 shares, generating $53,910 in total proceeds. Upon selling the shares at $15.00, the Chief Financial Officer now owns 60,138 shares.
Before that, Goeltz II Robert C. bought 3,594 shares. Arcus Biosciences Inc shares valued at $53,910 were divested by the Officer at a price of $15.00 per share.
H.C. Wainwright initiated its Arcus Biosciences Inc [RCUS] rating to a Neutral in a research note published on October 21, 2024; the price target was $20. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early October with a ‘”an Overweight”‘ rating. BofA Securities began covering RCUS with “Neutral” recommendation on November 18, 2022. Morgan Stanley started covering the stock on October 11, 2022. It rated RCUS as “an Overweight”.
Price Performance Review of RCUS
On Friday, Arcus Biosciences Inc [NYSE:RCUS] saw its stock jump 3.07% to $11.07. Over the last five days, the stock has lost -12.83%. Arcus Biosciences Inc shares have fallen nearly -25.65% since the year began. Nevertheless, the stocks have fallen -33.31% over the past one year. While a 52-week high of $20.31 was reached on 01/07/25, a 52-week low of $10.63 was recorded on 02/20/25. SMA at 50 days reached $14.18, while 200 days put it at $15.60.
Levels Of Support And Resistance For RCUS Stock
The 24-hour chart illustrates a support level at 10.70, which if violated will result in even more drops to 10.33. On the upside, there is a resistance level at 11.55. A further resistance level may holdings at 12.03. The Relative Strength Index (RSI) on the 14-day chart is 34.34, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.30, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.12%. Stochastics %K at 10.51% indicates the stock is a buying.
